Related Experiment Video
Updated: May 7, 2025
12:02
Molecular Evolution of the Tre Recombinase
Published on: May 29, 2008
9.7K
The Evolution of Treatment-Free Remission
Timothy P Hughes1, Agnes Sm Yong1, David M Ross2
1South Australian Health and Medical Research Institute, Adelaide, Australia.
Blood
|January 6, 2025
Summary
Treatment-free remission (TFR) is a major advance in chronic myeloid leukemia (CML) management, allowing some patients to stop tyrosine kinase inhibitor (TKI) therapy. Relapse is manageable, and TFR is becoming a more accessible goal for CML patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment.
- Deep molecular remissions sustainable off therapy, known as treatment-free remission (TFR), are now achievable in CML patients.
Purpose of the Study:
- To review the evolution and current status of TFR in CML.
- To discuss the broadening eligibility criteria, predictive markers, and safety of TFR.
- To outline future directions for TFR, aiming for broader patient access and shorter treatment durations.
Main Methods:
- Review of early pilot studies (e.g., French STIM, Australasian TWISTER) and subsequent clinical trials.
- Analysis of established consensus criteria for TFR eligibility.
- Examination of factors influencing TFR success and safety in a wider clinical context.
Main Results:
- Early TFR trials demonstrated feasibility but also the risk of rapid relapse.
- Relapsing patients can be safely and effectively retreated to deep molecular remission.
- TFR criteria have expanded, and safety is confirmed, yet it's achieved by a minority of CML patients.
Conclusions:
- TFR represents a significant achievement in CML therapy, moving towards a potential cure.
- Future efforts will focus on increasing TFR adoption, reducing therapy duration, and utilizing advanced TKIs and immune modulation.
- Predictive assays are expected to improve TFR success rates, making it a mainstream option for CML patients.
More Related Videos
08:20MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
13.8K
14:14Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR
Published on: December 6, 2014
16.4K
Related Concept Videos
01:10Retrovirus Life Cycles
45.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.3K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:30Electroconvulsive Therapy
16
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
16
02:50Combination Therapies and Personalized Medicine
4.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.7K
01:27Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
01:28Pulmonary Tuberculosis V
143
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
143